<code id='E7857F5A7E'></code><style id='E7857F5A7E'></style>
    • <acronym id='E7857F5A7E'></acronym>
      <center id='E7857F5A7E'><center id='E7857F5A7E'><tfoot id='E7857F5A7E'></tfoot></center><abbr id='E7857F5A7E'><dir id='E7857F5A7E'><tfoot id='E7857F5A7E'></tfoot><noframes id='E7857F5A7E'>

    • <optgroup id='E7857F5A7E'><strike id='E7857F5A7E'><sup id='E7857F5A7E'></sup></strike><code id='E7857F5A7E'></code></optgroup>
        1. <b id='E7857F5A7E'><label id='E7857F5A7E'><select id='E7857F5A7E'><dt id='E7857F5A7E'><span id='E7857F5A7E'></span></dt></select></label></b><u id='E7857F5A7E'></u>
          <i id='E7857F5A7E'><strike id='E7857F5A7E'><tt id='E7857F5A7E'><pre id='E7857F5A7E'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:comprehensive    - browse:146
          Christine Kao/STAT

          The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

          The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

          advertisement

          In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus